Oncoinvent to present three abstracts at EANM and ESMO 2026
Oslo, Norway – 30 September 2026 – Oncoinvent, a clinical-stage radiopharmaceutical company developing Radspherin®, a receptor-independent alpha-emitting therapy to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces that three abstracts from its Radspherin® program have been accepted for presentation at the European Association of Nuclear Medicine (EANM) Annual Congress 2026 in Vienna, Austria (17-21 October) and the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (23-27 October).
